Avacta Group Feed

	Est. tid*
2025-07-02	-	Årsstämma
2024-06-26	-	Årsstämma
2016-01-26	-	Split AVCT 100:1

Land	Storbritannien
Lista	52
Sektor	Hälsovård
Industri	Bioteknik

2026-05-19 08:14:37 Unaudited Preliminary Results for the Year Ended December 31, 2025

2026-05-06 08:00:00 Avacta presents new comparisons of pre|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026 71,00 GBP | -7,79% | 1,76 MGBP

2026-04-21 18:00:00 Avacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre|CISION® delivery platform 79,60 GBP | +3,38% | 2,56 MGBP

2026-04-14 13:26:11 Avacta CEO Christina Coughlin Named as One of In Vivo's 2026 Rising Leaders 72,00 GBP | +5,88% | 1,35 MGBP

2026-03-31 08:31:59 Avacta announces first patient treated in Phase 1 FOCUS-01 trial of FAP-Exd (AVA6103) - a sustained-release pre|CISION® exatecan peptide drug conjugate 63,50 GBP | -1,55% | 1,48 MGBP

2026-03-17 08:00:00 Avacta Announces Preclinical and Translational Presentations of pre|CISION® Platform Candidates at the 2026 AACR Annual Conference 69,00 GBP | -5,48% | 1,49 MGBP

2026-02-24 08:00:00 Avacta's pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis 62,50 GBP | +10,62% | 1,90 MGBP

2026-02-09 08:00:00 Avacta appoints Francis Wilson as Chief Scientific Officer 61,50 GBP | +1,65% | 1,15 MGBP

2026-01-21 14:03:29 Avacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre|CISION® Medicine, FAP-Exatecan (AVA6103) 55,50 GBP | +4,72% | 1,71 MGBP

2026-01-20 13:00:00 Avacta Announces Year-end Trading Update 53,00 GBP | -4,50% | 0,82 MGBP

2025-12-17 13:00:00 Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers 72,00 GBP | -8,86% | 7,90 MGBP

2025-10-25 19:14:00 Avacta presents first preclinical data from dual payload pre|CISION® medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets

2025-10-19 16:00:00 Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre|CISION® Platform at the European Society of Medical Oncology Annual Congress

2025-10-13 18:00:00 Avacta to Present First Dual Payload pre|CISION® Medicines Data at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets Symposium 71,00 GBP | +1,43% | 1,79 MGBP

2025-07-01 13:00:00 Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development 30,50 GBP | -1,61% | 0,43 MGBP

2025-05-28 13:00:00 Avacta Therapeutics Announces Appointments of Industry Veterans to Board of Directors 35,00 GBP | +12,90% | 2,31 MGBP

2025-04-28 13:01:00 Avacta Therapeutics Presents Data from Lead pre|CISION® Candidate FAP-Dox (AVA6000) at the 2025 AACR Annual Meeting 32,50 GBP | +3,17% | 1,40 MGBP

2025-03-31 13:00:00 Avacta Provides Business Update for the First Quarter of 2025 Outlining Progress Against Strategic Objectives 35,70 GBP | -7,15% | 0,61 MGBP

2025-03-26 12:00:00 Avacta Therapeutics Announces Presentations at 2025 AACR Annual Meeting 37,50 GBP | -0,66% | 0,29 MGBP

2025-03-07 15:28:22 Avacta Announces Promising Early Efficacy and Safety Data for AVA6000 in the Phase 1a Dose Escalation and Ongoing Enrollment in the Phase 1b Expansion Cohorts 36,50 GBP | +0,69% | 7,72 MGBP

2024-10-24 13:00:00 Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona 58,00 GBP | 0,00% | 3,79 MGBP

2024-10-17 13:00:00 Avacta Expands its Pipeline with Two Novel Assets Developed Using its pre|CISION® Platform 64,50 GBP | -0,15% | 1,58 MGBP

2024-10-15 08:00:00 Avacta Group strengthens executive team with appointment of Michelle Morrow, PhD as Chief Scientific Officer 60,00 GBP | -5,51% | 0,53 MGBP

2024-10-10 13:00:00 Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024 EORTC-NCI-AACR Symposium 57,00 GBP | +10,68% | 0,95 MGBP

2024-10-10 08:00:00 Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024 EORTC-NCI-AACR Symposium 57,00 GBP | +10,68% | 0,95 MGBP

2024-09-14 09:00:00 Avacta Reports Updated Phase 1 Clinical Data of AVA6000 at the European Society for Medical Oncology (ESMO) Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors

2024-09-09 00:05:00 Avacta to present updated clinical data on AVA6000 at the European Society for Medical Oncology (ESMO) Congress 70,00 GBP | -3,98%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Avacta Group

Kalender

Beskrivning

Vem äger bolaget?

Avacta Group

Kalender

Beskrivning

Vem äger bolaget?

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden